News

Remdesivir

Gilead Beats Fourth Quarter Estimates, Provides Upbeat Forecast for 2021

Reuters | Equities.com |

Gilead Sciences Inc (Nasdaq: GILD) on Thursday forecast its 2021 results above Wall Street estimates after posting a 26% rise in fourth-quarter 2020 revenue, driven by sales of its antiviral drug, remdesivir, which is used to treat COVID-19 patients.

Shares of Gilead were up 2.6% in extended trading.

Gilead said the COVID-19 pandemic continues to affect its sales, including its treatments for hepatitis C and HIV, due to fewer people going to their doctors. It expects a gradual recovery in underlying market dynamics starting the second quarter of this year.


Gilead Raises Full-Year Profit Forecast on Increased Demand for Antiviral Remdesivir

Reuters | Equities.com |

Gilead Sciences Inc raised its full-year profit forecast on Monday, as a recent resurgence in COVID-19 cases boosted demand for its COVID-19 treatment, remdesivir.

The level of new COVID-19 cases in the United States is starting to rise again, amidst the slow rollout of vaccine. Experts say the country should expect another surge in mid-January due to holiday gatherings.

The antiviral, currently authorized to treat COVID-19 patients across the world, was one of the drugs used to treat U.S. President Donald Trump’s coronavirus infection.


Global Health Experts Clash Over Use of Certain Drugs for COVID-19 Patients

AP News | Equities.com |

Health officials around the world are clashing over the use of certain drugs for COVID-19, leading to different treatment options for patients depending on where they live.

On Friday, a World Health Organization guidelines panel advised against using the antiviral remdesivir for hospitalized patients, saying there’s no evidence it improves survival or avoids the need for breathing machines.

But in the U.S. and many other countries, the drug has been the standard of care since a major, government-led study found other benefits — it shortened recovery time for hospitalized patients by five days on average, from 15 days to 10.


European Society of Intensive Care Medicine Advises Against Remdesivir in Sickest COVID-19 Patients

Reuters | Equities.com |

Antiviral remdesivir should not be used as a routine treatment for COVID-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.

Remdesivir, also known as Veklury, and steroid dexamethasone are the only drugs authorized to treat COVID-19 patients across the world. But the largest study on remdesivir’s efficacy, run by the World Health Organization (WHO), showed on Oct. 15 it had little or no impact, contradicting previous trials.


Gilead Sciences Gets FDA Approval for Remdesivir for Hospitalized COVID-19 Patients

Reuters | Equities.com |

(Reuters) - The U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Remdesivir, given intravenously, was one of the drugs used to treat U.S. President Donald Trump during his bout with COVID-19.

The FDA’s formal approval comes just hours before the president’s final debate with Democratic rival Joe Biden ahead of the Nov. 3 presidential election.


Gilead's Remdesivir Reduced COVID-19 Recovery Time by Five Days

Reuters | Equities.com |

Final data from Gilead Sciences Inc’s antiviral drug remdesivir showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said on Thursday.

In patients who were on oxygen when they first got the drug, remdesivir - sold under the brand Veklury - reduced recovery time by seven days compared with placebo after 29 days, according to the 1,062-patient study, published in the New England Journal of Medicine.


Stocks Rally Broadly; S&P 500 Index Climbs 1.8%

AP News | Equities.com |

Wall Street rallied Monday as hopes for economic aid from Washington helped it recover all its knee-jerk losses after learning President Donald Trump tested positive for the coronavirus.

The S&P 500 jumped 60.16 points, or 1.8%, to 3,408.60 amid widespread gains, with nine out of 10 stocks in the index rising. Energy producers and tech companies led the way.

Treasury yields, stocks overseas and oil all climbed after Trump and House Speaker Nancy Pelosi both noted the importance over the weekend of additional support for the economy. The market’s rally accelerated after Trump tweeted in the afternoon that he’ll leave the hospital, though his medical team said he “may not entirely be out of the woods yet.”


Eli Lilly Says Rheumatoid Arthritis Drug Combined With Remdesivir May Shorten COVID-19 Recovery Time

AP News | Equities.com |

A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day.

Eli Lilly announced the results Monday from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. The results have not yet been published or reviewed by independent scientists, but the government confirmed that Lilly’s statement was accurate.


Korea Reports Positive Preliminary Results With Remdesivir in Severe COVID-19

Reuters | Equities.com |

One in three South Korean patients seriously ill with COVID-19 showed an improvement in their condition after being given Gilead Sciences Inc’s antiviral remdesivir, health authorities said.

More research was needed to determine if the improvement was attributable to the drug or other factors such as patients’ immunity and other therapies, they said.

Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine...


Gilead Sciences Says Remdesivir Improved Clinical Recovery in COVID-19 Patients

Reuters | Equities.com |

Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir significantly improved clinical recovery and reduced the risk of death in COVID-19 patients.

The company said the finding requires confirmation in prospective clinical trials.

Gilead said it analyzed data from 312 patients treated in a late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity as in the st...


Sponsored Financial Content

Market Movers